Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
‍
Are you a health professional practicing in the United States?
Yes, take me to Medical Affairs
No, Take me to ParatekPharma.com

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Medical Information Request
Publications & Presentations
Grants & Funding
Product Resources
Disease Education Resources
Medical Affairs
Publications & Presentations

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscript Icon
Manuscripts
Poster Icon
Posters

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Clear all
Apply
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Non-Clinical
Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis
Resource Type
Manuscript
Areas of Interest
Biothreats
Author Name
Heine
Citation #
68(9):e0059524
Date
September 2024
Pharmacokinetics - Pharmacodynamics
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Bhavnani
Citation #
online ahead of print
Date
July 2024
Review
Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Draper
Citation #
online ahead of print
Date
July 2024
Real World Evidence
Case Report of Severe Chlamydia psittaci Pneumonia Treated with Omadacycline
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Chen
Citation #
17:659-663
Date
July 2024
Microbiology
Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Acinetobacter baumannii Patient Isolates
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Halim
Citation #
12, 1353
Date
July 2024
Pharmacokinetics - Pharmacodynamics
Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Zhang
Citation #
46(8):629-635
Date
July 2024
Microbiology
Nosocomial transmission of tet(x3), blaNDM-1 and blaOXA-97-carrying Acinetobacter baumannii conferring resistance to eravacycline and omadacycline, the Netherlands, March to August 2021
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Talsma
Citation #
29(28):2400019.
Date
July 2024
Non-Clinical
Efficacies of omadacycline + amikacin + imipenem and an alloral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Ignatius
Citation #
e00381-24
Date
July 2024
Real World Evidence
Severe community-acquired pneumonia caused by Chlamydia abortus in China: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Yang
Citation #
11:1426577
Date
July 2024
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Serio
Citation #
68(7):e0063824
Date
June 2024
Real World Evidence
Bilateral Jaw Mycobacterium Abscessus Mimicking Actinomycosis: A Postoperative Complication of Wisdom Teeth Extraction
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Johanis
Citation #
16(6):e62336
Date
June 2024
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Rimal
Citation #
146:102482
Date
May 2024
Non-Clinical
In vitro activity of omadacycline against clinical isolates of Nocardia
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Pham
Citation #
68(5):e0168623
Date
May 2024
Real World Evidence
Efficacy of omadacycline in the treatment of Legionella pneumonia: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wang
Citation #
14:1380312
Date
May 2024
Non-Clinical
Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Boorgula
Citation #
147:102519
Date
May 2024
Pharmacokinetics - Pharmacodynamics
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Xu
Citation #
online ahead of print
Date
April 2024
Pharmacokinetics - Pharmacodynamics
Evaluating omadacycline dosing regimens against drug-resistant pathogens including Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wei
Citation #
online ahead of print
Date
April 2024
Non-Clinical
Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Hu
Citation #
1236:124057
Date
April 2024
Non-Clinical
Antipsychotic Nature of Antibiotics Vancomycin and Omadacycline Combination Ameliorating Stress in a Zebrafish Model
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Raj
Citation #
16(3):e56195
Date
March 2024
Clinical
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline versus Vancomycin in Healthy Volunteers
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Jo
Citation #
229(1):273-281.
Date
January 2024
Real World Evidence
Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Guillain-Barre Syndrome
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wang
Citation #
17; 81-87
Date
January 2024
Non-Clinical
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Ruiz
Citation #
81: e21-e29
Date
January 2024
Non-Clinical
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model
Resource Type
Manuscript
Areas of Interest
Other
Author Name
Singh
Citation #
Online ahead of print
Date
December 2023
Real World Evidence
Omadacycline for the treatment of Legionella pneumophila pneumonia caused by drowning: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Lu
Citation #
14(6):481-483
Date
November 2023
Show More Resources
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2024
IDWeek
accordio_arrow
IDWeek 2024
NACF
accordio_arrow
NACF 2024
MHSRS
accordio_arrow
MHSRS 2024
ASM Microbe
accordio_arrow
ASM Microbe 2024
MAD-ID
accordio_arrow
MAD-ID 2024
ESCMID Global (formally ECCMID)
accordio_arrow
ESCMID Global (formally ECCMID)
Texas Medical Center AMR & Stewardship
accordio_arrow
Texas Medical Center AMR & Stewardship
2023
ECCMID
accordio_arrow
ECCMID 2023
ASM Microbe
accordio_arrow
ASM Microbe 2023
IDWeek
accordio_arrow
IDWeek 2023
2022
CO Mycobacterium Conference
accordio_arrow
CO Mycobacterium Conference
MAD-ID
accordio_arrow
MAD-ID 2022
ASM-Microbe
accordio_arrow
ASM-Microbe 2022
MHSRS
accordio_arrow
MHSRS 2022
IDWeek
accordio_arrow
IDWeek 2022
No items found.
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
View All
Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-Inferiority, Randomized Controlled Trial
In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020
Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) among Outpatient and Urgent Care Visits
Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023)
Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects
Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex
Pharmacokinetics of omadacycline in adults with cystic fibrosis
Omadacycline is Active Against Multidrug Resistant Bacillus Anthracis Strains Resistant to Tetracyclines
Evaluation of Omadacycline Treatment for Osteomyelitis
In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae
Omadacycline as Salvage Therapy for Pulmonary Mycobacterium Abscessus Complex
Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline
Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections
​​Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury (ALI)
Real-World Outpatient Use of Omadacycline for Bone and Joint Infections
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
A Functional OMICS Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits
In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme
Gut microbiome diversity and bacterial taxonomic group changes in healthy volunteers receiving oral omadacycline or vancomycin
Quantifying antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacteria infections: an opportunity for novel agents?
Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)
A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
Bile Acid Concentrations in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin
Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Clinical Response to Intravenous versus Oral Treatment in Patients with Acute Bacterial Skin and Skin Structure Infections
Omadacycline is not a Substrate for Clinically Relevant Beta-Lactamase Enzymes
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
No items found.
No items found.
No items found.

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

MSD Contact Form
Cancel
Thank you! Your submission has been received!
Close
Oops! Something went wrong while submitting the form.

By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.

Medical Information
If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com
Submit an Inquiry
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).
Report an Adverse Event
To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Submit an Adverse Event Report
Request follow-up from a Medical Science Director
If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.
Contact an MSD

Privacy Policy | Terms and Conditions | Social Media Guidelines | Compliance Program | Expanded Access Policy

© 2024 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-COR-0050-01 06/24